网络安全检测|网络安全服务|网络安全扫描-香港墨客投资移动版

This technology makes it possible for cardiologists to access the heart through the apex by a minimally invasive procedure. Access to the apex is closed by using only surgical suture and not leaving any devices in the heart. When this technology is used widely, thousands of people in the world will become eligible for medical treatment of their structural heart illnesses. With the current state of structural heart therapy, these patients have either to undergo open heart surgery or be limited to care available through the femoral vein access. On the day of the First In Man, deployment of the newly developed instrument helped to save the lives of two people in Kazakhstan, who are now on their way to recovery.

Prof. Anthony Nobles, Chairman, CEO and Chief Clinical Specialist of HeartStitch®, Inc., stated, "This is a historical day for all of us, w. Whenever we perform a First In Man ofwith one of our new technologies, we recognize that we are entrusted with not only the lives of these patients, but the hopes of tens of thousands of patients thatmore who in the future will rely on this procedure for their lives. As a scientist there is no greater measure of your work than the ability to save a life. As a businessman we are, I am also proud of the impact this has had on the people of Kazakhstan, -our partners in this development. The ability It''s been very gratifying to demonstrate the incredible talent and expertise of the doctors, engineers and all involved in bringing this technology to reality both in Kazakhstan and the USA. The HeartStitch® TA is one of ourthe greatest examples of our worldwide collaboration. I am personally very proud forto have had this opportunity to work with Dr. Pya, who I believe is one of the most talented cardiac surgeons in the world. We believe this is also a historic moment for Kazakhstan to show the world that It''s all proof positive that real medical innovation is not only possible here in Kazakhstan, but will continue to grow aswill continue to grow with this collaboration with Heartstitch. This moment marks significant growth of a new industry."

This was a historic day for the Cardiac Center, HeartStitch, Inc. and Nazarbayev University. This invention has the potential of revolutionizing the field of cardiology. Transapical access opens a door to several types of medical care previously not available to many patients and can improve the quality of care compared with the currently available technology. With time, as cardiologists use this technology on a daily basis, everyone will remember that it started in Kazakhstan.

About Nazarbayev University

Nazarbayev University is a modern and rapidly developing international university located in the heart of Eurasia - Astana, the capital of the Republic of Kazakhstan. The University serves as a cluster designed to create favorable conditions for innovators, assist in introducing the results of research and development to the market, and form a ring of research-intensive and technology companies around Nazarbayev University. It must also create a favorable environment for researchers, attracting investments to new technology research within Nazarbayev University, developing engineering potential in Kazakhstan, fostering transfer and commercialization of cutting-edge technologies, and creating jobs for Nazarbayev University alumni.

For more on Nazarbayev Univeristy visit 

About National Cardiac Research Center

The National Cardiac Research Center is the leading Cardiac Surgery Organization in Central Asia, offering medical services and high-quality service. It was established by the order of the President of the Republic of Kazakhstan N. A. Nazarbayev and opened theits doors on October 12, 2011.

The main clinical directions of the Center are:

- Treatment of the congenital and acquired heart diseases;

- Coronary heart disease;

- Heart failure;

- Cardiac rhythm disturbance.

For more on National Cardiac Research Center visit 

About HeartStitch®

HeartStitch® Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace. HeartStitch® is focused on the innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures. HeartStitch HeartStitch® currently markets under license the NobleStitch™ EL device for cardiovascular suturing and PFO closure. HeartStitch™ develops new structural heart technologies through its international innovation development teams in California, Kazakhstan and Germany.

The HeartStitch® TA is FDA cleared for vascular suturing in the United States. For more on HeartStitch® visit 

HeartStitch® is a registered trademark of HeartStitch, Inc.

HeartStitch® TA for cardiac suturing and transapical access and closure